Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16136666 | 0.82 | HTR2C (0.37) | HTR2CHTR2BHTR2ATDP1 | |
| SCHEMBL6601250 | 0.81 | HTR2C (0.35) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL30092890 | 0.79 | HTR2C (0.61) | HTR2CCHRNB2CHRNA4HTR2BHTR2A | |
| SCHEMBL29589456 | 0.78 | HTR2C (0.56) | HTR2CCHRNB2CHRNA4HTR2BGAA | |
| SCHEMBL457401 | 0.78 | HTR2C (0.56) | HTR2CCHRNB2CHRNA4HTR2BGAA | |
| SCHEMBL29484307 | 0.78 | HTR2C (0.56) | HTR2CCHRNB2CHRNA4HTR2BGAA | |
| SCHEMBL4522448 | 0.77 | GID4 (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL4533549 | 0.77 | KDM1A (0.40) | HTR2CCHRNB2CHRNA4HTR2BHTR2A | |
| SCHEMBL30397619 | 0.77 | KDM1A (0.40) | HTR2CCHRNB2CHRNA4HTR2BHTR2A | |
| SCHEMBL9786158 | 0.77 | KDM1A (0.40) | HTR2CCHRNB2CHRNA4HTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| US-7250413-B2 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050256096-A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256096-A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CHCHD6, NAT10, RPS25 | HTR2C 4684/4885CHRNB2 4551/4885CHRNA4 4443/4885 |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | HTR2C 463/4885CHRNB2 2040/4885CHRNA4 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.